The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

Topic engagement Tell us about the 5 key areas for quality improvement which you consider as having the greatest potential to improve the quality of care in this area. Closing date for comments: ...

NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the ...

Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults. Last reviewed: 25 June 2025 Next review: This guidance will be reviewed if ...

Sparsentan (Filspari, Vifor) is indicated for 'the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥ 1.0 g/day (or urine protein-to-creatinine ratio ...

Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any ...

primary IgA nephropathy affects approximately 18,000 people in England 47.71% of these people have chronic kidney disease (CKD) stages 1-3 based on company internal market research 47.18% of people ...

When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has immunoglobulin A ...

What this means in practice Sparsentan must be funded in the NHS in England to treat primary IgAN in adults with a urine protein excretion of 1.0 g/day or more, or a UPCR of 0.75 g/g or more, if it is ...

NICE is unable to make a recommendation on fosdenopterin (Nulibry) for treating molybdenum cofactor deficiency type A in people of all ages. This is because Sentynl Therapeutics has withdrawn from the ...